Neurocrine Biosciences (NASDAQ:NBIX) is set to give its latest quarterly earnings report on Monday, 2025-05-05. Here's what investors need to know before the announcement. Analysts estimate that ...

Neurocrine Biosciences NBIX is set to give its latest quarterly earnings report on Monday, 2025-05-05. Here's what investors need to know before the announcement. Analysts estimate that Neurocrine ...

today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC ( “Concentra”), whereby Concentra will acquire Kronos Bio for $0.57 in ...

About Harmony Biosciences Holdings Inc. Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of ...

SAN DIEGO, April 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and ...

Engine Biosciences NetMAPPR platform integrates AI, functional genomics, and translational science to uncover and prosecute key genetic interactions and tumor-specific vulnerabilities. Leveraging ...

SAN DIEGO, April 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and ...

Cytek Biosciences, Inc. is highlighting its Full Spectrum Profiling™ (FSP®) technology at the upcoming CYTO 2025 and IMMUNOLOGY2025 conferences to promote advancements in cell analysis.

SAN DIEGO, CA - Avidity Biosciences, Inc. (NASDAQ:RNA), a biotechnology firm specializing in pharmaceutical preparations with a market capitalization of $3.85 billion, has announced a change in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation ...